Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids.

Literature DB >> 3829046

Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids.

Abstract

Recent developments of hybridoma technology have allowed us to prepare a bispecific monoclonal antibody recognising both the tumour-associated antigen carcinoembryonic antigen (CEA) and the cytostatic vinca alkaloids. The yields of the hybrid-hybrid 28.19.8 monoclonal after affinity chromatography purification are close to 50% of the total Ig produced. The hybrid-hybrid has a molecular weight ca. 150,000 daltons. The heavy chains of the hybrid-hybrid are a gamma 1 heavy chain from the parental anti-CEA monoclonal and a gamma 2a heavy chain from the anti-vinca alkaloid donor lymphocytes.

Entities: Chemical Gene Species

Mesh：

Substances：

Year: 1987 PMID： 3829046 DOI： 10.1007/bf00205589

Source DB: PubMed Journal: Cancer Immunol Immunother ISSN： 0340-7004 Impact factor: 6.968

19 in total

1. Drug localisation and growth inhibition studies of vindesine-monoclonal anti-CEA conjugates in a human tumour xenograft.

Authors: G F Rowland; R G Simmonds; V A Gore; C H Marsden; W Smith
Journal: Cancer Immunol Immunother Date: 1986 Impact factor: 6.968

2. Coupling of enzymes to proteins with glutaraldehyde. Use of the conjugates for the detection of antigens and antibodies.

Authors: S Avrameas
Journal: Immunochemistry Date: 1969-01

3. Use of monoclonal antibodies for the histopathological diagnosis of human malignancy.

Authors: K C Gatter; Z Abdulaziz; P Beverley; J R Corvalan; C Ford; E B Lane; M Mota; J R Nash; K Pulford; H Stein; J Taylor-Papadimitriou; C Woodhouse; D Y Mason
Journal: J Clin Pathol Date: 1982-11 Impact factor: 3.411

4. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

Authors: S L Morrison; M J Johnson; L A Herzenberg; V T Oi
Journal: Proc Natl Acad Sci U S A Date: 1984-11 Impact factor: 11.205

5. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells.

Authors: Z Steplewski; M D Lubeck; H Koprowski
Journal: Science Date: 1983-08-26 Impact factor: 47.728

6. Lymphocyte-dependent antibodies to antigen 3.1, a cell-surface antigen expressed by a subgroup of human melanomas.

Authors: I Hellström; K E Hellström; M Y Yeh
Journal: Int J Cancer Date: 1981-03-15 Impact factor: 7.396

7. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors: D Herlyn; H Koprowski
Journal: Proc Natl Acad Sci U S A Date: 1982-08 Impact factor: 11.205

8. Antitumor properties of vindesine-monoclonal antibody conjugates.

Authors: G F Rowland; C A Axton; R W Baldwin; J P Brown; J R Corvalan; M J Embleton; V A Gore; I Hellström; K E Hellström; E Jacobs
Journal: Cancer Immunol Immunother Date: 1985 Impact factor: 6.968

9. Localization of an anti-CEA monoclonal antibody in colo-rectal carcinoma xenografts.

Authors: M V Pimm; N C Armitage; A C Perkins; W Smith; R W Baldwin
Journal: Cancer Immunol Immunother Date: 1985 Impact factor: 6.968

10. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies.

Authors: T J Kipps; P Parham; J Punt; L A Herzenberg
Journal: J Exp Med Date: 1985-01-01 Impact factor: 14.307

15 in total

Review 1. Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors: S Songsivilai; P J Lachmann
Journal: Clin Exp Immunol Date: 1990-03 Impact factor: 4.330

Review 2. Therapeutic strategies with monoclonal antibodies and immunoconjugates.

Authors: V S Byers; R W Baldwin
Journal: Immunology Date: 1988-11 Impact factor: 7.397

Review 3. Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors: C H Ford; V J Richardson; V S Reddy
Journal: Indian J Pediatr Date: 1990 Jan-Feb Impact factor: 1.967

4. Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.

Authors: L K Gilliland; M R Clark; H Waldmann
Journal: Proc Natl Acad Sci U S A Date: 1988-10 Impact factor: 11.205

5. Interleukin-2 receptors on rat eosinophils in adjuvant arthritis.

Authors: S C Meacock; D R Brandon; W Smith
Journal: Immunology Date: 1991-09 Impact factor: 7.397

6. The production of a bispecific anti-CEA, anti-hapten (4-amino-phthalate) hybrid-hybridoma.

Authors: F Lloyd; M Goldrosen
Journal: J Natl Med Assoc Date: 1991-10 Impact factor: 1.798

7. Modulation of drug-induced cytotoxicity by a bispecific monoclonal antibody that recognizes the epidermal growth factor receptor and doxorubicin.

Authors: D Morelli; A Sardini; E Villa; M L Villa; S Ménard; M I Colnaghi; A Balsari
Journal: Cancer Immunol Immunother Date: 1994-03 Impact factor: 6.968

8. Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody.

Authors: J R Corvalan; W Smith; V A Gore; D R Brandon; P J Ryde
Journal: Cancer Immunol Immunother Date: 1987 Impact factor: 6.968

9. Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids.

Authors: J R Corvalan; W Smith; V A Gore; D R Brandon
Journal: Cancer Immunol Immunother Date: 1987 Impact factor: 6.968

10. Effect of a bifunctional monoclonal antibody directed against a tumor marker and doxorubicin on the growth of epidermoid vulvar carcinoma grafted in athymic mice.

Authors: D Morelli; S Ménard; B Pozzi; A Balsari; M I Colnaghi
Journal: Cell Biophys Date: 1994